2'-Fucosyllactose Composition for Intestinal Barrier Integrity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current infant formulas lack the optimal composition to effectively mimic the beneficial effects of human milk, particularly in maintaining intestinal barrier integrity and counteracting virus-induced disruptions, as they do not adequately incorporate fucosylated human milk oligosaccharides like 2′-fucosyllactose, which are crucial for immune system development and barrier function.
Innovation Solution
A nutritional composition comprising fucosylated human milk oligosaccharides, preferably 2′-fucosyllactose, is administered to improve and maintain intestinal barrier integrity, combined with other non-digestible oligosaccharides and long-chain polyunsaturated fatty acids, to treat and prevent virus-induced intestinal barrier disruptions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If infant formula is used as a substitute for human milk, then nutritional support is provided, but intestinal barrier integrity is not adequately maintained and virus-induced disruptions are not effectively counteracted
Solution Approach 1:
The patent modifies the chemical composition parameters of infant formula by incorporating specific fucosylated human milk oligosaccharides (2'-fucosyllactose, lacto-N-neotetraose, lacto-N-fucopentaose) at defined concentrations (0.1-5 g/L for 2'-FL, 0.01-2 g/L for LNnT and LNFp). This parameter change enables the formula to maintain intestinal barrier integrity and counteract virus-induced disruptions, resolving the contradiction between providing nutritional support and maintaining barrier function.
Solution Approach 2:
The patent creates a composite nutritional composition combining multiple components: fucosylated HMOs (2'-FL, LNnT, LNFp), long-chain polyunsaturated fatty acids (DHA, ARA), and other standard infant formula nutrients. This composite formulation synergistically maintains intestinal barrier integrity and provides protection against viral infections, addressing both aspects of the technical contradiction simultaneously.
2Adaptability or versatility
If human milk oligosaccharides are added to infant formula, then prebiotic effects and immune system development are promoted, but the formula composition becomes more complex
Solution Approach 1:
The patent applies local quality by selectively incorporating specific types of HMOs (fucosylated varieties: 2'-FL, LNnT, LNFp) rather than using a complete random mixture of all possible HMO structures. This targeted selection maintains the prebiotic benefits and immune support functions while simplifying the overall composition structure, making the formula more manageable for production and regulation.
Solution Approach 2:
The patent achieves multi-functionality by selecting HMOs that simultaneously provide multiple benefits: 2'-fucosyllactose serves as a prebiotic, immune modulator, and barrier protector; lacto-N-neotetraose and lacto-N-fucopentaose similarly provide multiple functions. This universal approach allows a single composition to address diverse needs (prebiotic effects, immune development, barrier integrity) without requiring separate additives for each function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly reduces alpha-1 antitrypsin levels in the gut wash, indicating improved intestinal barrier function and reduced permeability, effectively treating and preventing virus-induced disruptions and enhancing overall intestinal health.
Implementation Method 1
HMOS are neither absorbed nor metabolized in the proximal gut and reach the distal gut undigested to exert prebiotic effects on certain bacterial populations, to reinforce the intestinal barrier and to protect against enteropathogen infections.
Implementation Method 2
In vitro and in vivo studies with 2′-FL have evidenced its immunomodulatory effects, which include promoting anti-inflammatory activities and the inhibition of the colonization of pathogens.
Data Source
AI summary
The invention concerns composition comprising 2′-fucosyllactose for use in the treatment of virus induced diarrhea.